Overview

Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

Status:
Unknown status

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

In this phase II study, the investigators are aiming to explore lenalidomide combined with R-CHOP (R2-CHOP) in newly diagnosed double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL)

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Lenalidomide